PILA PHARMA AB
Norra Vallgatan 72
211 22 Malmö
Sweden
pilapharma.com
Malmö, 30 September 2025
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON
PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY
P
ILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs fortreatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest in thespace, that it has signed a contract with Danish preclinical Contract Research Organisation, Gubra.
The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity.
During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof- of-concept on bodyweight regulation / obesity in first rats and then in humans.
The net proceeds of the unit rights issue, in July, provided the Company with finances to conduct preclinical trials of the Company's clinical drug candidate XEN-D0501 in obesity.
The associated warrants of series TO2 will have it's subscription period between 5 and 15 February 2026 after the read-out of the rat studies. The net proceeds from the warrants are intended to finance clinical trials of the Company's clinical drug candidate XEN-D0501 in obesity.
The new collaboration with Gubra will facilitate the first step to demonstrate proof-of-concept in obese rats.
The discussions on choice of obesity model and study design were initiated already in July when a "slot" in Gubra's research facility was also reserved. With all details now settled, the contract is signed.
It has been chosen to study the effect of 4 weeks of treatment with PILA PHARMA's TRPV1-inhibitor drug candidate XEN-D0501 in both obese male DIO and Zucker rats. The DIO rat is a standard obesity model where normal rats are fed a high fat diet to induce obesity. The Zucker rat is another relevant obesity model where rats
due to a mutation spontaneously overeat and develop obesity on a normal diet, simply due to the excess amount of calories consumed.
Læs hele meddelelsen:
https://cdn.bequoted.com/media/1/ab31b090-37c5-420d-954d-98a76cfc4ad2/PILA_PHARMA_Pressrelease_2025-09-30.pdf
Pharma har en betalt IR-aftale med ProInvestor.com
Norra Vallgatan 72
211 22 Malmö
Sweden
pilapharma.com
Malmö, 30 September 2025
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON
PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY
P
ILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs fortreatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest in thespace, that it has signed a contract with Danish preclinical Contract Research Organisation, Gubra.
The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity.
During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof- of-concept on bodyweight regulation / obesity in first rats and then in humans.
The net proceeds of the unit rights issue, in July, provided the Company with finances to conduct preclinical trials of the Company's clinical drug candidate XEN-D0501 in obesity.
The associated warrants of series TO2 will have it's subscription period between 5 and 15 February 2026 after the read-out of the rat studies. The net proceeds from the warrants are intended to finance clinical trials of the Company's clinical drug candidate XEN-D0501 in obesity.
The new collaboration with Gubra will facilitate the first step to demonstrate proof-of-concept in obese rats.
The discussions on choice of obesity model and study design were initiated already in July when a "slot" in Gubra's research facility was also reserved. With all details now settled, the contract is signed.
It has been chosen to study the effect of 4 weeks of treatment with PILA PHARMA's TRPV1-inhibitor drug candidate XEN-D0501 in both obese male DIO and Zucker rats. The DIO rat is a standard obesity model where normal rats are fed a high fat diet to induce obesity. The Zucker rat is another relevant obesity model where rats
due to a mutation spontaneously overeat and develop obesity on a normal diet, simply due to the excess amount of calories consumed.
Læs hele meddelelsen:
https://cdn.bequoted.com/media/1/ab31b090-37c5-420d-954d-98a76cfc4ad2/PILA_PHARMA_Pressrelease_2025-09-30.pdf
Pharma har en betalt IR-aftale med ProInvestor.com
Opdateret analyse af Pila Pharma fra Aktieinfo den 23. september
Stærk finansiel position efter en stærkt overtegnet (293%) kapitalrejsning i juli. Uændret kursmål på 7 SEK (aktuel kurs på 2,38 svarer til en værdiansættelse på kun cirka 100 mio. SEK).
Det strategiske skifte mod fedme - "bet on obesity" - har givet casen en hurtigere bane til et af de største vækstmarkeder i pharma, ifølge Goldman Sachs vurderes fedmemarkedet at nå ca. 95 mia. USD i 2030, mens Morgan Stanley ser potentiale for omkring 150 mia. USD på toppen omkring 2035.
Pila Pharmas prækliniske fedmedata, der ventes i Q1 2026, udgør den næste væsentlige kursdriver. Dialoger med større farmaselskaber har bekræftet interessen for selskabets orale og differentierede TRPV1-baserede tilgang, hvis proof-of-concept kan demonstreres.
https://www.aktieinfo.net/filer/pilapharma23092025.pdf
Stærk finansiel position efter en stærkt overtegnet (293%) kapitalrejsning i juli. Uændret kursmål på 7 SEK (aktuel kurs på 2,38 svarer til en værdiansættelse på kun cirka 100 mio. SEK).
Det strategiske skifte mod fedme - "bet on obesity" - har givet casen en hurtigere bane til et af de største vækstmarkeder i pharma, ifølge Goldman Sachs vurderes fedmemarkedet at nå ca. 95 mia. USD i 2030, mens Morgan Stanley ser potentiale for omkring 150 mia. USD på toppen omkring 2035.
Pila Pharmas prækliniske fedmedata, der ventes i Q1 2026, udgør den næste væsentlige kursdriver. Dialoger med større farmaselskaber har bekræftet interessen for selskabets orale og differentierede TRPV1-baserede tilgang, hvis proof-of-concept kan demonstreres.
https://www.aktieinfo.net/filer/pilapharma23092025.pdf
